Search

Your search keyword '"Kumada, Hiromitsu"' showing total 299 results
Start Over Author "Kumada, Hiromitsu" Search Limiters Available in Library Collection
299 results on '"Kumada, Hiromitsu"'

2. A Phase 1b Study of Lenvatinib plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116.

Author

Kudo, Masatoshi, Finn, Richard S., Ikeda, Masafumi, Sung, Max W., Baron, Ari D., Okusaka, Takuji, Kobayashi, Masahiro, Kumada, Hiromitsu, Kaneko, Shuichi, Pracht, Marc, Meyer, Tim, Nagao, Satoshi, Saito, Kenichi, Mody, Kalgi, Ramji, Zahra, Dubrovsky, Leonid, and Llovet, Josep M.

Subjects
PROGRESSION-free survival, OVERALL survival, HEPATOCELLULAR carcinoma, PATIENT safety, ANTINEOPLASTIC agents
Abstract

Introduction: Lenvatinib (dosing for patients who weigh ≥60 kg was 12 mg/day; for patients who weigh <60 kg, the dose was 8 mg/day) plus pembrolizumab 200 mg once every 3 weeks demonstrated antitumor activity and a manageable safety profile in patients with first-line unresectable hepatocellular carcinoma (uHCC) in the open-label phase 1b Study 116/KEYNOTE-524 (primary analysis data cutoff date: October 31, 2019; median follow-up: 10.6 months). This analysis (updated data cutoff date: March 31, 2021) reports efficacy results from 17 months of additional follow-up time. Methods: 100 patients with uHCC were included in the primary analysis (median follow-up: 27.6 months). Endpoints included overall survival (OS), investigator-assessed progression-free survival (PFS), objective response rate (ORR), and duration of response (DOR) per modified RECIST. Landmark analyses of OS by the best response at 3 and 9 months were performed. Pembrolizumab antidrug antibodies (ADAs) and concentrations were also measured (cutoff date: August 7, 2020). Results: ORR was 43.0% (95% CI 33.1–53.3%) and median DOR was 17.1 months (95% CI 6.9–19.3 months). Median PFS and OS were 9.3 months (95% CI 7.4–9.8 months) and 20.4 months (95% CI 14.4–25.9 months), respectively. No treatment-emergent ADAs were detected. Conclusion: Results show a sustained treatment effect with lenvatinib plus pembrolizumab in patients with uHCC in the first-line setting. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. Long-term Favorable Efficacy of Regular and Repeated Hospitalizations with a Personalized Diet and Exercise Treatment for Steatotic Liver Disease

Author

Akuta, Norio, primary, Kawamura, Yusuke, additional, Sezaki, Hitomi, additional, Nakamichi, Kenichi, additional, Saegusa, Eiji, additional, Ogura, Hidetoshi, additional, Kato, Masaki, additional, Doi, Etsuko, additional, Inoue, Naoko, additional, Hosaka, Tetsuya, additional, Saitoh, Satoshi, additional, Kobayashi, Mariko, additional, Fujiyama, Shunichiro, additional, Arase, Yasuji, additional, Ikeda, Kenji, additional, Suzuki, Yoshiyuki, additional, Kumada, Hiromitsu, additional, and Suzuki, Fumitaka, additional

Published
2024
Full Text
View/download PDF

4. A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis

Author

Fujiwara, Naoto, Kobayashi, Masahiro, Fobar, Austin J., Hoshida, Ayaka, Marquez, Cesia A., Koneru, Bhuvaneswari, Panda, Gayatri, Taguri, Masataka, Qian, Tongqi, Raman, Indu, Li, Quan-Zhen, Hoshida, Hiroki, Sezaki, Hitomi, Kumada, Hiromitsu, Tateishi, Ryosuke, Yokoo, Takeshi, Yopp, Adam C., Chung, Raymond T., Fuchs, Bryan C., Baumert, Thomas F., Marrero, Jorge A., Parikh, Neehar D., Zhu, Shijia, Singal, Amit G., and Hoshida, Yujin

Published
2021
Full Text
View/download PDF

5. A Phase 1b Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116

Author

Kudo, Masatoshi, primary, Finn, Richard S., additional, Ikeda, Masafumi, additional, Sung, Max W., additional, Baron, Ari D., additional, Okusaka, Takuji, additional, Kobayashi, Masahiro, additional, Kumada, Hiromitsu, additional, Kaneko, Shuichi, additional, Pracht, Marc, additional, Meyer, Tim, additional, Nagao, Satoshi, additional, Saito, Kenichi, additional, Mody, Kalgi, additional, Ramji, Zahra, additional, Dubrovsky, Leonid, additional, and Llovet, Josep M., additional

Published
2023
Full Text
View/download PDF

6. Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma

Author

Finkin, Shlomi, Yuan, Detian, Stein, Ilan, Taniguchi, Koji, Weber, Achim, Unger, Kristian, Browning, Jeffrey L, Goossens, Nicolas, Nakagawa, Shigeki, Gunasekaran, Ganesh, Schwartz, Myron E, Kobayashi, Masahiro, Kumada, Hiromitsu, Berger, Michael, Pappo, Orit, Rajewsky, Klaus, Hoshida, Yujin, Karin, Michael, Heikenwalder, Mathias, Ben-Neriah, Yinon, and Pikarsky, Eli

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Liver Disease, Rare Diseases, Liver Cancer, Cancer, Stem Cell Research, Digestive Diseases, 2.1 Biological and endogenous factors, Aetiology, Adaptive Immunity, Animals, Carcinoma, Hepatocellular, Comparative Genomic Hybridization, Cytokines, Disease Models, Animal, Hepatocytes, Humans, I-kappa B Kinase, Immunity, Innate, Immunoblotting, In Situ Hybridization, Liver Neoplasms, Lymphoid Tissue, Mice, Inbred C57BL, Mice, Knockout, Mice, Transgenic, NF-kappa B, Neoplastic Stem Cells, Reverse Transcriptase Polymerase Chain Reaction, Stem Cell Niche, T-Lymphocytes, Transcriptome, Biochemistry and cell biology
Abstract

Ectopic lymphoid-like structures (ELSs) are often observed in cancer, yet their function is obscure. Although ELSs signify good prognosis in certain malignancies, we found that hepatic ELSs indicated poor prognosis for hepatocellular carcinoma (HCC). We studied an HCC mouse model that displayed abundant ELSs and found that they constituted immunopathological microniches wherein malignant hepatocyte progenitor cells appeared and thrived in a complex cellular and cytokine milieu until gaining self-sufficiency. The egress of progenitor cells and tumor formation were associated with the autocrine production of cytokines previously provided by the niche. ELSs developed via cooperation between the innate immune system and adaptive immune system, an event facilitated by activation of the transcription factor NF-κB and abolished by depletion of T cells. Such aberrant immunological foci might represent new targets for cancer therapy.

Published
2015

9. Switching from entecavir to tenofovir disoproxil fumarate for HBeAg-positive chronic hepatitis B patients: a phase 4, prospective study

Author

Suzuki, Fumitaka, Suzuki, Yoshiyuki, Karino, Yoshiyasu, Tanaka, Yasuhito, Kurosaki, Masayuki, Yatsuhashi, Hiroshi, Atarashi, Tomofumi, Atsukawa, Masanori, Watanabe, Tsunamasa, Enomoto, Masaru, Kudo, Masatoshi, Maeda, Naoto, Kohno, Hiroshi, Joko, Kouji, Michitaka, Kojiro, Miki, Koichiro, Takahashi, Kazuhiro, Ide, Tatsuya, Fujiyama, Shigetoshi, Kohno, Tomoko, Itoh, Hiroshi, Tsukamoto, Sakiyo, Suzuki, Yuko, Kawano, Yoshiaki, Sugiura, Wataru, and Kumada, Hiromitsu

Published
2021
Full Text
View/download PDF

11. Efficacy of the Combination of Systemic Sequential Therapy and Locoregional Therapy in the Long-Term Survival of Patients with BCLC Stage C Hepatocellular Carcinoma

Author

Kawamura, Yusuke, primary, Akuta, Norio, additional, Shindoh, Junichi, additional, Matsumura, Masaru, additional, Okubo, Satoshi, additional, Tominaga, Licht, additional, Fujiyama, Shunichiro, additional, Hosaka, Tetsuya, additional, Saitoh, Satoshi, additional, Sezaki, Hitomi, additional, Suzuki, Fumitaka, additional, Suzuki, Yoshiyuki, additional, Ikeda, Kenji, additional, Arase, Yasuji, additional, Hashimoto, Masaji, additional, Kozuka, Takuyo, additional, and Kumada, Hiromitsu, additional

Published
2023
Full Text
View/download PDF

16. Favorable impact of long‐term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5‐year follow‐up study

Author

Akuta, Norio, primary, Kawamura, Yusuke, additional, Fujiyama, Shunichiro, additional, Saito, Satoshi, additional, Muraishi, Nozomu, additional, Sezaki, Hitomi, additional, Hosaka, Tetsuya, additional, Kobayashi, Masahiro, additional, Kobayashi, Mariko, additional, Arase, Yasuji, additional, Ikeda, Kenji, additional, Suzuki, Fumitaka, additional, Suzuki, Yoshiyuki, additional, and Kumada, Hiromitsu, additional

Published
2022
Full Text
View/download PDF

18. Changes in the Mean Intrahepatic Target Computed Tomography Attenuation Value During Treatment May be a Useful New Predictor of the Post-progression Survival Associated with Lenvatinib Treatment

Author

Muraishi, Nozomu, primary, Kawamura, Yusuke, additional, Kobayashi, Masahiro, additional, Shindoh, Junichi, additional, Kobayashi, Yuta, additional, Okubo, Satoshi, additional, Iritani, Soichi, additional, Fujiyama, Shunichiro, additional, Hosaka, Tetsuya, additional, Saitoh, Satoshi, additional, Sezaki, Hitomi, additional, Akuta, Norio, additional, Suzuki, Fumitaka, additional, Suzuki, Yoshiyuki, additional, Ikeda, Kenji, additional, Arase, Yasuji, additional, Hashimoto, Masaji, additional, Yasuda, Ichiro, additional, and Kumada, Hiromitsu, additional

Published
2022
Full Text
View/download PDF

20. Long-term histological impact of sodium-glucose co-transporter-2 inhibitor for non-alcoholic steatohepatitis complicated by diabetes mellitus: 3 cases evaluated by liver histology at 3 years after the start of treatment

Author

Kobayashi Masahiro, Arase Yasuji, Fujiyama Shun'ichiro, Hosaka Tetsuya, Kawamura Yusuke, Kobayashi Mariko, Akuta Norio, Saito Satoshi, Suzuki Yoshiyuki, Suzuki Fumitaka, Ikeda Kenji, Sezaki Hitomi, and Kumada Hiromitsu

Subjects
medicine.medical_specialty, Hepatology, business.industry, Sodium, chemistry.chemical_element, Transporter, Non alcoholic, medicine.disease, Gastroenterology, chemistry, Internal medicine, Diabetes mellitus, medicine, Steatohepatitis, Liver histology, business
Published
2020

22. Ultrasensitive Assay for Hepatitis B Core‐Related Antigen Predicts Hepatocellular Carcinoma Incidences During Entecavir

Author

Hosaka, Tetsuya, primary, Suzuki, Fumitaka, additional, Kobayashi, Mariko, additional, Fujiyama, Shunichiro, additional, Kawamura, Yusuke, additional, Sezaki, Hitomi, additional, Akuta, Norio, additional, Kobayashi, Masahiro, additional, Suzuki, Yoshiyuki, additional, Saitoh, Satoshi, additional, Arase, Yasuji, additional, Ikeda, Kenji, additional, and Kumada, Hiromitsu, additional

Published
2021
Full Text
View/download PDF

24. ゲノタイプ2/1組み換えC型肝炎ウイルス感染患者3例に対して奏功した直接作用型抗ウイルス剤投与

Author

Okada, Masako, Hoang, Hai, Tamori, Akihiro, Uchida-Kobayashi, Sawako, Enomoto, Masaru, Kumada, Hiromitsu, and Kawada, Norifumi

Subjects
ゲノタイプ2/1組み換えC型肝炎ウイルス, virus diseases, HCV genotype 2/1, Chimeric HCV, Direct-acting antivirals, digestive system diseases, C型肝炎ウイルス, 直接作用型抗ウイルス剤
Abstract

There have been a few reports on the treatment of patients infected with recombinant hepatitis C virus (HCV) genotype 2/1 strains with direct acting antivirals (DAAs). We experienced three patients with genotype 2/1 recombinant HCV, treated with DAAs successfully. The first, a 39-year-old man, was infected with recombinant HCV genotype 2a/1b, a rare variant....

Published
2018

25. Additional file 2 of Mortality rates and risk factors in 1412 Japanese patients with decompensated hepatitis C virus-related cirrhosis: a retrospective long-term cohort study

Author

Shunichiro Fujiyama, Akuta, Norio, Sezaki, Hitomi, Kobayashi, Mariko, Kawamura, Yusuke, Hosaka, Tetsuya, Kobayashi, Masahiro, Saitoh, Satoshi, Fumitaka Suzuki, Suzuki, Yoshiyuki, Arase, Yasuji, Ikeda, Kenji, and Kumada, Hiromitsu

Subjects
body regions, digestive system diseases
Abstract

Additional file 2. Figure 2. Cumulative 15-year survival rates by MELD score in patients with decompensated HCV-related cirrhosis without HCC (N = 379). The rates differed significantly between patients with MELD score ≧ 7 and < 7 (log-rank test, P = 0.0017). HCV, hepatitis C virus. MELD, Model for End-stage Liver Disease.

Published
2021
Full Text
View/download PDF

26. Additional file 1 of Mortality rates and risk factors in 1412 Japanese patients with decompensated hepatitis C virus-related cirrhosis: a retrospective long-term cohort study

Author

Shunichiro Fujiyama, Akuta, Norio, Sezaki, Hitomi, Kobayashi, Mariko, Kawamura, Yusuke, Hosaka, Tetsuya, Kobayashi, Masahiro, Saitoh, Satoshi, Fumitaka Suzuki, Suzuki, Yoshiyuki, Arase, Yasuji, Ikeda, Kenji, and Kumada, Hiromitsu

Subjects
body regions
Abstract

Additional file 1. Figure 1. Cumulative 15-year survival rates by MELD score in patients with decompensated HCV-related cirrhosis (N = 969). The rates differed significantly between patients with MELD score ≧ 7 and < 7 (log-rank test, P = 0.0012). HCV, hepatitis C virus. MELD, Model for End-stage Liver Disease.

Published
2021
Full Text
View/download PDF

29. Antiviral activity, dose–response relationship, and safety of entecavir following 24-week oral dosing in nucleoside-naive Japanese adult patients with chronic hepatitis B: a randomized, double-blind, phase II clinical trial

Author

Shindo, Michiko, Chayama, Kazuaki, Mochida, Satoshi, Toyota, Joji, Tomita, Eiichi, Kumada, Hiromitsu, Yokosuka, Osamu, Sata, Michio, Hayashi, Norio, Suzuki, Kazuyuki, Okanoue, Takeshi, Tsubouchi, Hirohito, Ishikawa, Hiroki, Seriu, Taku, and Omata, Masao

Published
2009
Full Text
View/download PDF

30. Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B

Author

Kobashi, Haruhiko, Fujioka, Shin-ichi, Kawaguchi, Mitsuhiko, Kumada, Hiromitsu, Yokosuka, Osamu, Hayashi, Norio, Suzuki, Kazuyuki, Okanoue, Takeshi, Sata, Michio, Tsubouchi, Hirohito, Sato, Chifumi, Kiyosawa, Kendo, Tanikawa, Kyuichi, Seriu, Taku, Ishikawa, Hiroki, Takaki, Akinobu, Iwasaki, Yoshiaki, Osawa, Toshiya, Takaki, Toshiyuki, Sakaguchi, Kosaku, Shiratori, Yasushi, Yamamoto, Kazuhide, Tenney, Daniel J., and Omata, Masao

Published
2009
Full Text
View/download PDF

31. Efficacy and Safety of Ramucirumab in Patients with Unresectable Hepatocellular Carcinoma with Progression after Treatment with Lenvatinib

Author

Kasuya, Kayoko, primary, Kawamura, Yusuke, additional, Kobayashi, Masahiro, additional, Shindoh, Junichi, additional, Kobayashi, Yuta, additional, Kajiwara, Akira, additional, Iritani, Soichi, additional, Fujiyama, Shunichiro, additional, Hosaka, Tetsuya, additional, Saitoh, Satoshi, additional, Sezaki, Hitomi, additional, Akuta, Norio, additional, Suzuki, Fumitaka, additional, Suzuki, Yoshiyuki, additional, Ikeda, Kenji, additional, Arase, Yasuji, additional, Eguchi, Yuichiro, additional, Hashimoto, Masaji, additional, and Kumada, Hiromitsu, additional

Published
2021
Full Text
View/download PDF

32. (18)F-Fluorodeoxyglucose Uptake in Hepatocellular Carcinoma as a Useful Predictor of an Extremely Rapid Response to Lenvatinib

Author

Kawamura, Yusuke, Kobayashi, Masahiro, Shindoh, Junichi, Kobayashi, Yuta, Kasuya, Kayoko, Sano, Tomoya, Fujiyama, Shunichiro, Hosaka, Tetsuya, Saitoh, Satoshi, Sezaki, Hitomi, Akuta, Norio, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Ikeda, Kenji, Arase, Yasuji, Hashimoto, Masaji, and Kumada, Hiromitsu

Subjects
Original Paper
Abstract

BACKGROUND AND AIMS: This study aimed to identify the utility of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) as a predictor of the response of hepatocellular carcinoma (HCC) to lenvatinib. METHODS: We evaluated 28 consecutive patients with HCC diagnosed by dynamic CT or magnetic resonance imaging combined with 18F-FDG-PET/CT. The tumor-to-normal liver standardized uptake value ratio (TLR) of the target tumor was measured before treatment using 18F-FDG-PET/CT, with a TLR ≥2 classified as a high potential for malignant HCC. The treatment response was evaluated 2 weeks after the initiation of lenvatinib using modified Response Evaluation Criteria in Solid Tumors. RESULTS: Of the 28 patients, 12 (43%) presented with a TLR ≥2. Evaluation of the treatment response at 2 weeks in these 12 patients revealed that 2 (17%) exhibited a complete response, 8 (67%) a partial response, 2 (17%) stable disease, and none with progressive disease. Therefore, 10 of the 12 patients (83%) experienced an objective response to lenvatinib. On the other hand, 7 of the 16 patients with a TLR

Published
2019

33. Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial

Author

Ikeda, Masafumi, Kudo, Masatoshi, Aikata, Hiroshi, Nagamatsu, Hiroaki, Ishii, Hiroshi, Yokosuka, Osamu, Torimura, Takuji, Morimoto, Manabu, Ikeda, Kenji, Kumada, Hiromitsu, Sato, Tosiya, Kawai, Ikuko, Yamashita, Toru, Horio, Hiroshi, Okusaka, Takuji, and Miriplatin TACE Study Group

Subjects
carbohydrates (lipids), Randomized controlled trial, Carcinoma, Miriplatin, polycyclic compounds, Hepatocellular, Chemoembolization, Therapeutic, skin and connective tissue diseases, Epirubicin
Abstract

Background: This prospective study investigated the superiority of transarterial chemoembolization (TACE) with miriplatin over TACE with epirubicin regarding overall survival (OS) in patients with unresectable hepatocellular carcinoma (HCC). Methods: Patients with unresectable HCC were randomized 1:1 to receive TACE with miriplatin or epirubicin in lipiodol. The primary endpoint was OS; secondary endpoints were percentages of patients who achieved treatment effect (TE) 4 (100% necrotizing effect or tumor reduction), duration of time to TACE failure, and adverse events (AEs). OS was compared using a stratified log-rank test adjusted for clinical stage, Child–Pugh class, and institution. Results: Of 257 patients enrolled from August 2008 to August 2010, 247 were analyzed for efficacy and toxicity (miriplatin, n = 124; epirubicin, n = 123). Baseline characteristics were well balanced between the two groups. Median OS times were 1111 days for miriplatin and 1127 days for epirubicin (adjusted hazard ratio 1.01, 95% confidence interval 0.73–1.40, P = 0.946). TE4 rates were 44.4% for miriplatin and 37.4% for epirubicin. Median times to TACE failure were 365.5 days for miriplatin and 414.0 days for epirubicin. AEs of grade 3 or higher, including elevated aspartate aminotransferase (miriplatin, 39.5%; epirubicin, 57.7%) and elevated alanine aminotransferase (miriplatin, 31.5%; epirubicin, 53.7%), were less frequent in the miriplatin than the epirubicin group. Conclusions: OS after TACE with miriplatin was not superior to that after TACE with epirubicin; however, hepatic AEs were less frequent with miriplatin.

Published
2018

34. Diagnosis and Resection Treatment of Triplet Hepatocellular Carcinomas with a non-B non-C Background in a Middle Aged Man over a Period of 6-years

Author

Kajiwara, Akira, primary, Kinowaki, Keiichi, additional, Akuta, Norio, additional, Kasuya, Kayoko, additional, Muraishi, Nozomu, additional, Iritani, Soichi, additional, Kawamura, Yusuke, additional, Fujiyama, Shunichiro, additional, Sezaki, Hitomi, additional, Hosaka, Tetsuya, additional, Saitoh, Satoshi, additional, Kobayashi, Masahiro, additional, Kobayashi, Mariko, additional, Arase, Yasuji, additional, Ikeda, Kenji, additional, Suzuki, Fumitaka, additional, Kumada, Hiromitsu, additional, and Suzuki, Yoshiyuki, additional

Published
2020
Full Text
View/download PDF

35. Two subtypes of genotype B (Ba and Bj) of hepatitis B virus in Japan

Author

Sugauchi, Fuminaka, Kumada, Hiromitsu, Sakugawa, Hiroshi, Komatsu, Masafumi, Niitsuma, Hirofumi, Watanabe, Hisayoshi, Akahane, Yoshihiro, Tokita, Hajime, Kato, Takanobu, Tanaka, Yasuhito, Orito, Etsuro, Ueda, Ryuzo, Miyakawa, Yuzo, and Mizokami, Masashi

Subjects
Genotype -- Research, Hepatitis B virus -- Care and treatment, Hepatitis B virus -- Research, Health, Health care industry
Published
2004

36. Ultrasensitive Assay for Hepatitis B Core‐Related Antigen Predicts Hepatocellular Carcinoma Incidences During Entecavir.

Author

Hosaka, Tetsuya, Suzuki, Fumitaka, Kobayashi, Mariko, Fujiyama, Shunichiro, Kawamura, Yusuke, Sezaki, Hitomi, Akuta, Norio, Kobayashi, Masahiro, Suzuki, Yoshiyuki, Saitoh, Satoshi, Arase, Yasuji, Ikeda, Kenji, and Kumada, Hiromitsu

Subjects
CHRONIC hepatitis B, HEPATITIS associated antigen, HEPATITIS B, HEPATOCELLULAR carcinoma, CIRCULAR DNA, CELL surface antigens, BIOMARKERS
Abstract

Serum hepatitis B core‐related antigen (HBcrAg) and surface antigen (HBsAg) are surrogate markers of intrahepatic covalently closed circular DNA. The measurement range of the current HBcrAg assay is relatively narrow. Thus, we examined the potential of HBcrAg and HBsAg measured by ultrasensitive assays for predicting hepatocellular carcinoma (HCC) development in patients with chronic hepatitis B treated with entecavir (ETV). We conducted a retrospective cohort study of 180 patients who received ETV for >1 year. All patients had hepatitis B e‐antigen negativity at baseline. Serum HBcrAg and HBsAg levels at baseline and year 1 were measured in all patients by ultrasensitive assays using immunoassay for total antigen including complex by pretreatment (iTACT) technology. During the median follow‐up of 11.0 years, 22 patients developed HCC (11.8/1,000 person‐years). Baseline HBsAg levels were not associated with HCC development during ETV treatment. However, high HBcrAg levels at baseline and at year 1 were significantly associated with HCC development (log‐rank test; P < 0.001). In 110 patients (61.1%) with ≥4.0 log U/mL at baseline (high HBcrAg cohort), HBcrAg declined to ≤2.9 log U/mL at year 1 in 25 patients (22.7%). The adjusted hazard ratio for HCC incidence was significantly lower in patients with HBcrAg ≤2.9 log U/mL at year 1 than in those in the high HBcrAg cohort. Conclusion: Measurement of HBcrAg by ultrasensitive assay has better potential for predicting HCC during antiviral treatment than the current HBcrAg assay. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

38. SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver Histopathology

Author

Akuta, Norio, primary, Kawamura, Yusuke, additional, Fujiyama, Shunichiro, additional, Sezaki, Hitomi, additional, Hosaka, Tetsuya, additional, Kobayashi, Masahiro, additional, Kobayashi, Mariko, additional, Saitoh, Satoshi, additional, Suzuki, Fumitaka, additional, Suzuki, Yoshiyuki, additional, Arase, Yasuji, additional, Ikeda, Kenji, additional, and Kumada, Hiromitsu, additional

Published
2020
Full Text
View/download PDF

39. Fulminant Hepatitis due to de novo Hepatitis B after Cord Blood Transplantation Rescued by Medical Treatment

Author

Sano, Tomoya, primary, Akuta, Norio, additional, Suzuki, Yoshiyuki, additional, Kasuya, Kayoko, additional, Fujiyama, Shunichiro, additional, Kawamura, Yusuke, additional, Sezaki, Hitomi, additional, Hosaka, Tetsuya, additional, Saitoh, Satoshi, additional, Kobayashi, Masahiro, additional, Suzuki, Fumitaka, additional, Kobayashi, Mariko, additional, Arase, Yasuji, additional, Ikeda, Kenji, additional, and Kumada, Hiromitsu, additional

Published
2020
Full Text
View/download PDF

40. Predictors of Insulin Secretion in Japanese Patients with Histopathologically-confirmed Non-alcoholic Fatty Liver Disease

Author

Akuta, Norio, primary, Kawamura, Yusuke, additional, Fujiyama, Shunichiro, additional, Sezaki, Hitomi, additional, Hosaka, Tetsuya, additional, Kobayashi, Masahiro, additional, Kobayashi, Mariko, additional, Saitoh, Satoshi, additional, Suzuki, Fumitaka, additional, Suzuki, Yoshiyuki, additional, Arase, Yasuji, additional, Ikeda, Kenji, additional, and Kumada, Hiromitsu, additional

Published
2020
Full Text
View/download PDF

41. Poorly Differentiated Hepatocellular Carcinoma in a Low-risk Patient with an Otherwise Normal Liver

Author

Ogasawara, Nobuhiko, primary, Saitoh, Satoshi, additional, Denpou, Hideyuki, additional, Kinowaki, Keiichi, additional, Akuta, Norio, additional, Suzuki, Fumitaka, additional, Hashimoto, Masashi, additional, Fujiyama, Shunichiro, additional, Kawamura, Yusuke, additional, Sezaki, Hitomi, additional, Hosaka, Tetsuya, additional, Kobayashi, Masahiro, additional, Suzuki, Yoshiyuki, additional, Arase, Yasuji, additional, Ikeda, Kenji, additional, Fujii, Takeshi, additional, and Kumada, Hiromitsu, additional

Published
2020
Full Text
View/download PDF

42. Pretreatment Heterogeneous Enhancement Pattern of Hepatocellular Carcinoma May Be a Useful New Predictor of Early Response to Lenvatinib and Overall Prognosis

Author

Kawamura, Yusuke, primary, Kobayashi, Masahiro, additional, Shindoh, Junichi, additional, Kobayashi, Yuta, additional, Kasuya, Kayoko, additional, Sano, Tomoya, additional, Fujiyama, Shunichiro, additional, Hosaka, Tetsuya, additional, Saitoh, Satoshi, additional, Sezaki, Hitomi, additional, Akuta, Norio, additional, Suzuki, Fumitaka, additional, Suzuki, Yoshiyuki, additional, Ikeda, Kenji, additional, Arase, Yasuji, additional, Hashimoto, Masaji, additional, and Kumada, Hiromitsu, additional

Published
2020
Full Text
View/download PDF

43. Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular Carcinoma

Author

Kawamura, Yusuke, primary, Kobayashi, Masahiro, additional, Shindoh, Junichi, additional, Kobayashi, Yuta, additional, Okubo, Satoshi, additional, Tominaga, Licht, additional, Kajiwara, Akira, additional, Kasuya, Kayoko, additional, Iritani, Soichi, additional, Fujiyama, Shunichiro, additional, Hosaka, Tetsuya, additional, Saitoh, Satoshi, additional, Sezaki, Hitomi, additional, Akuta, Norio, additional, Suzuki, Fumitaka, additional, Suzuki, Yoshiyuki, additional, Ikeda, Kenji, additional, Arase, Yasuji, additional, Hashimoto, Masaji, additional, Kozuka, Tokuyo, additional, and Kumada, Hiromitsu, additional

Published
2020
Full Text
View/download PDF

44. 18F-Fluorodeoxyglucose Uptake in Hepatocellular Carcinoma as a Useful Predictor of an Extremely Rapid Response to Lenvatinib

Author

Kawamura, Yusuke, primary, Kobayashi, Masahiro, additional, Shindoh, Junichi, additional, Kobayashi, Yuta, additional, Kasuya, Kayoko, additional, Sano, Tomoya, additional, Fujiyama, Shunichiro, additional, Hosaka, Tetsuya, additional, Saitoh, Satoshi, additional, Sezaki, Hitomi, additional, Akuta, Norio, additional, Suzuki, Fumitaka, additional, Suzuki, Yoshiyuki, additional, Ikeda, Kenji, additional, Arase, Yasuji, additional, Hashimoto, Masaji, additional, and Kumada, Hiromitsu, additional

Published
2019
Full Text
View/download PDF

45. Circulating MicroRNA‐122 and Fibrosis Stage Predict Mortality of Japanese Patients With Histopathologically Confirmed NAFLD

Author

Akuta, Norio, primary, Kawamura, Yusuke, additional, Arase, Yasuji, additional, Saitoh, Satoshi, additional, Fujiyama, Shunichiro, additional, Sezaki, Hitomi, additional, Hosaka, Tetsuya, additional, Kobayashi, Masahiro, additional, Kobayashi, Mariko, additional, Suzuki, Yoshiyuki, additional, Suzuki, Fumitaka, additional, Ikeda, Kenji, additional, and Kumada, Hiromitsu, additional

Published
2019
Full Text
View/download PDF

48. JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2016 update for genotype 1 and 2

Author

Masayuki Kurosaki, Kazuhiko Koike, Fumitaka Suzuki, Norio Hayashi, Hiroshi Yotsuyanagi, Hajime Takikawa, Hirohito Tsubouchi, Naoki Hiramatsu, Kumada Hiromitsu, Namiki Izumi, Yasuhiro Asahina, Atsushi Tanaka, Eiji Tanaka, and Yasuhito Tanaka

Subjects
Hepatology, business.industry, Hepatitis C virus, MEDLINE, medicine.disease_cause, Virology, 03 medical and health sciences, 0302 clinical medicine, Infectious Diseases, 030220 oncology & carcinogenesis, Genotype, medicine, 030211 gastroenterology & hepatology, business
Published
2016

49. Role of NS5A-L31/Y93 Double Wild-type in Failure of Glecaprevir/Pibrentasvir Double Therapy in Two Patients with a History of Direct-acting Antiviral Agent Failure: An Ultra-deep Sequencing Analysis

Author

Sano, Tomoya, primary, Akuta, Norio, additional, Suzuki, Fumitaka, additional, Kasuya, Kayoko, additional, Fujiyama, Shunichiro, additional, Kawamura, Yusuke, additional, Sezaki, Hitomi, additional, Hosaka, Tetsuya, additional, Saitoh, Satoshi, additional, Kobayashi, Masahiro, additional, Suzuki, Yoshiyuki, additional, Kobayashi, Mariko, additional, Arase, Yasuji, additional, Ikeda, Kenji, additional, and Kumada, Hiromitsu, additional

Published
2019
Full Text
View/download PDF

50. Abstract CT061: A Phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results

Author

Ikeda, Masafumi, primary, Sung, Max W., additional, Kudo, Masatoshi, additional, Kobayashi, Masahiro, additional, Baron, Ari D., additional, Finn, Richard S., additional, Kaneko, Shuichi, additional, Zhu, Andrew X., additional, Kubota, Tomoki, additional, Kralijevic, Silvija, additional, Ikezawa, Hiroki, additional, Siegel, Abby B., additional, Kumada, Hiromitsu, additional, and Okusaka, Takuji, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results